This is an extract of the current NICE guidelines for use of CGMs -
"Continuous glucose monitoring
NICE's diagnostics guidance on integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes is being updated. The guidance is being updated as a multiple technology appraisal and will assess hybrid closed loop systems.
1.6.10Offer adults with type 1 diabetes a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM, commonly referred to as 'flash'), based on their individual preferences, needs, characteristics, and the functionality
of the devices available. See box 1 for examples of factors to consider as part of this discussion.
[2022]
1.6.11When choosing a
continuous glucose monitoring (CGM) device:
- use shared decision making to identify the person's needs and preferences, and offer them an appropriate device
- if multiple devices meet their needs and preferences, offer the device with the lowest cost. [2022]" My highlights in blue.
Pragmatically, Dexcom are offering the Dexcom 1 to compete head to head with Abbots' Libre 2/3. Also they are hopeful (probably initially the US market) that D1 will also appeal to the very much larger T2 market.
But NICE guidelines are just that - the latest CGM advice was only published last August, most clinics will still be struggling to see how to accommodate more use within their current prescribing budgets, including availability of CGM trained staff to support users, etc - sadly I suspect this will last well into their 2023/4 cycles.
Are you already a Libre/Dexcom user? If yes, what functionality are you worried about if prescribed a Dexcom 1?
<edited for spelling>